| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LCAT |
| Uniprot No | P04180 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-440aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMFWLLN VLFPPHTTPK AELSNHTRPV ILVPGCLGNQ LEAKLDKPDV VNWMCYRKTE DFFTIWLDLN MFLPLGVDCW IDNTRVVYNR SSGLVSNAPG VQIRVPGFGK TYSVEYLDSS KLAGYLHTLV QNLVNNGYVR DETVRAAPYD WRLEPGQQEE YYRKLAGLVE EMHAAYGKPV FLIGHSLGCL HLLYFLLRQP QAWKDRFIDG FISLGAPWGG SIKPMLVLAS GDNQGIPIMS SIKLKEEQRI TTTSPWMFPS RMAWPEDHVF ISTPSFNYTG RDFQRFFADL HFEEGWYMWL QSRDLLAGLP APGVEVYCLY GVGLPTPRTY IYDHGFPYTD PVGVLYEDGD DTVATRSTEL CGLWQGRQPQ PVHLLPLHGI QHLNMVFSNL TLEHINAILL GAYRQGPPAS PTASPEPPPP E |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于LCAT重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**：**"Expression and Characterization of Recombinant Human Lecithin-Cholesterol Acyltransferase"**
**作者**：Francone et al.
**摘要**：该研究报道了在哺乳动物细胞(CHO细胞)中成功表达重组人LCAT蛋白，并验证其酶活性。通过体外实验证实，重组LCAT能够有效催化胆固醇酯化，为后续研究其在脂代谢中的作用及治疗应用奠定了基础。
---
2. **文献名称**：**"Production of Functional Recombinant LCAT in Escherichia coli for Therapeutic Development"**
**作者**：Jin et al.
**摘要**：研究团队利用大肠杆菌表达系统生产重组LCAT蛋白，并通过优化包涵体复性工艺获得高活性产物。实验表明，重组蛋白在动物模型中显著提高HDL胆固醇水平，提示其潜在治疗动脉粥样硬化的价值。
---
3. **文献名称**：**"Recombinant LCAT Enhances Reverse Cholesterol Transport and Ameliorates Familial LCAT Deficiency"**
**作者**：Kuivenhoven et al.
**摘要**：通过腺病毒载体在小鼠体内表达重组LCAT，发现其能恢复家族性LCAT缺乏症模型的脂代谢异常，减少角膜浑浊和肾脏损伤，为基因治疗该遗传病提供了实验依据。
---
4. **文献名称**：**"Structural and Functional Analysis of Recombinant LCAT Using Cryo-EM"**
**作者**：Zhang et al.
**摘要**：利用冷冻电镜解析了重组LCAT的三维结构，揭示了其底物结合域和催化机制的关键位点。研究为设计靶向LCAT的调节剂(如治疗低HDL血症)提供了结构生物学依据。
---
以上文献涵盖了LCAT重组蛋白的表达系统开发、治疗潜力验证及结构功能研究，可满足不同研究需求。如需具体文献链接或补充年份，请进一步说明。
Lecithin-cholesterol acyltransferase (LCAT) is a crucial enzyme in lipid metabolism, primarily synthesized in the liver and circulated in the plasma. It plays a pivotal role in high-density lipoprotein (HDL) maturation by catalyzing the esterification of free cholesterol to form cholesteryl esters, which are sequestered within the lipoprotein core. This process, known as the LCAT reaction, is essential for reverse cholesterol transport (RCT), a mechanism that removes excess cholesterol from peripheral tissues to the liver for excretion. LCAT deficiency, whether genetic (e.g., familial LCAT deficiency or fish-eye disease) or acquired, is associated with abnormal lipid profiles, corneal opacities, and accelerated atherosclerosis, highlighting its physiological significance.
Recombinant LCAT protein, produced via genetic engineering in expression systems such as mammalian cells (e.g., CHO cells) or microbial platforms, has emerged as a therapeutic candidate. Its development aims to address LCAT-deficient disorders and potentially treat cardiovascular diseases linked to impaired RCT. Early studies demonstrated that infusing recombinant LCAT in animal models or humans restores HDL functionality, reduces lipid accumulation, and improves vascular health. However, challenges persist in optimizing production yield, stability, and post-translational modifications (e.g., glycosylation) to ensure biological activity.
Recent research explores engineered LCAT variants with enhanced enzymatic activity or resistance to inhibitors, as well as delivery strategies like gene therapy or nanoparticle carriers. Additionally, recombinant LCAT serves as a tool to study HDL metabolism and evaluate drug candidates targeting lipid disorders. Despite promising preclinical data, clinical translation requires further validation of long-term efficacy and safety. Overall, recombinant LCAT represents a bridge between understanding lipid biology and developing targeted therapies for metabolic and cardiovascular diseases.
×
